| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Dipartimento di Neuroscienze, Unità Operativa di Neurologia, Ospedale Bellaria, Bologna, Italia (R.P., F.P., F.S., I.B., R.M., C.A.T.); Istituto di Ematologia e Oncologia Medica "Seràgnoli" (M.C., E.Z., P.T., D.C., P.T.) and Istituto di Cardiologia (E.P.), Ospedale S. Orsola-Malpighi, Università di Bologna, Italia.
Address correspondence and reprint requests to Dr. Rosaria Plasmati, Dipartimento di Neuroscienze, Unità Operativa di Neurologia, Ospedale Bellaria, Via Altura 3, 40100, Bologna, Italy rosaria.plasmati{at}ausl.bo.it
Background: Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity.
Objective: To study the occurrence of both myeloma-related neuropathy and thalidomide-induced neuropathy in 31 patients with newly diagnosed MM.
Methods: Clinical and electrophysiologic examinations were performed in 31 patients with newly diagnosed MM before and after 4 months of therapy with thalidomide (200 mg/day, total dose: 21 g) aimed at debulking MM, before autologous transplantation. After transplantation, the patients took thalidomide, 200 mg/day for another 3 months (total dose over three months: 18 g) and then underwent a final clinical and electrophysiologic checkup.
Results: At baseline, four patients presented a mild sensorimotor peripheral neuropathy related to MM, which tended to worsen slightly during treatment with thalidomide. At the end of treatment, 83% of the patients had clinical and electrophysiologic evidence of a mild sensory rather than motor, axonal, length-dependent polyneuropathy, whereas 100% of the patients showed improvement to the basic pathology (
partial response).
Conclusions: Peripheral neuropathy, sometimes subclinical, and mild in our patients, is a common, early side effect of thalidomide therapy. The high doses (21 g) used in all patients for a relatively short time (4 months) rule out any correlations between neuropathy, total dose, and duration of treatment.
Supplemental data at www.neurology.org
Disclosure: The authors report no conflicts of interest.
Received May 8, 2006. Accepted in final form March 8, 2007.
This article has been cited by other articles:
|
|
 |
|
  M. Cavo, L. Pantani, P. Tacchetti, M. C. Pallotti, A. Brioli, A. Petrucci, E. Zamagni, and P. Tosi Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies J. Clin. Oncol., November 10, 2009; 27(32): e186 - e187. [Full Text] [PDF]
|
|
|
|
|
|
M. Cavo, F. Di Raimondo, E. Zamagni, F. Patriarca, P. Tacchetti, A. F. Casulli, S. Volpe, G. Perrone, A. Ledda, M. Ceccolini, et al. Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma J. Clin. Oncol., October 20, 2009; 27(30): 5001 - 5007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Layzer and J. Wolf MYELOMA-ASSOCIATED POLYNEUROPATHY RESPONDING TO LENALIDOMIDE Neurology, September 8, 2009; 73(10): 812 - 813. [Full Text] [PDF]
|
|
|
|
|
|
P. G. Richardson, W. Xie, C. Mitsiades, A. A. Chanan-Khan, S. Lonial, H. Hassoun, D. E. Avigan, A. L. Oaklander, D. J. Kuter, P. Y. Wen, et al. Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy J. Clin. Oncol., July 20, 2009; 27(21): 3518 - 3525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Zara, M Ermani, R Rondinone, S Arienti, and A Doria Thalidomide and sensory neurotoxicity: a neurophysiological study J. Neurol. Neurosurg. Psychiatry, November 1, 2008; 79(11): 1258 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Murillo Jr, J. E. Cox, and M. S. Oholendt An Overview of Chemotherapy-Induced Peripheral Neuropathy Journal of Pharmacy Practice, April 1, 2008; 21(2): 138 - 145. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
